Non-penetrating filtering surgery with MMC

Article

Non-penetrating filtering surgery with intraoperative mitomycin C (MMC) and without a scleral implant, can provide reasonable intraocular pressure (IOP) control.

Non-penetrating filtering surgery with intraoperative mitomycin C (MMC) and without a scleral implant, can provide reasonable intraocular pressure (IOP) control, according to Esther Arranz-Marquez and co-workers from the Vissum Corporacion Oftalmologica de Madrid, Spain.

A prospective trial enrolled 131 patients with primary open angle glaucoma (POAG) to undergo non-penetrating filtering surgery with MMC and without an implant. Patients were followed-up at one day and one, three, six, nine and 12 months postoperatively.

Mean preoperative IOP was 20.2±5.2 mmHg. At each follow-up a reduction in IOP was recorded (p=0.001): 12.3±4.2, 13.7±4.6, 13.7±3.6, 14.2±4.0, 14.1±3.6 at one, three, six, nine and 12 months, respectively. Further, the mean number of medications reduced from 1.8±0.7 to 0.1±0.4 12 months postoperatively. Goniopuncture was carried out in 31 eyes and three eyes were re-operated on due to inadequate IOP control.

At the study's conclusion, the authors believed that this procedure offers reasonable IOP control with few postoperative complications.

Related Videos
Ana Neves, head of global marketing for ZEISS Meditec Ophthalmology
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Scott D Barnes, MD, CMO of STAAR Surgical
Tomislav Bucalic, head of marketing at Geuder, and David Geuder, member of the executive board and CIO
Related Content
© 2023 MJH Life Sciences

All rights reserved.